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ABSTRACT  
 
 The migration from legacy fee-for-service reimbursement to payments linked to high value health 
care is accelerating in the United States because of new legislation and re-design of payments from 
the Centers for Medicare and Medicaid Services (CMS).  Since patients with chronic diseases 
account for substantial use of health care resources, payers and health systems are focusing on 
maximizing the value of care for these patients. Since chronic liver diseases  impose a major health 
burden worldwide affecting the health and lives of many individuals and families as well as 
substantial costs for individuals and payers, hepatologists must understand how they can improve 
their practices . Hepatologists practice a high-intensity cognitive sub-specialty, using complex and 
costly procedures and medications. High value patient care requires multi-disciplinary coordination, 
labor-intensive support for critically ill patients and effective chronic disease management. Under 
current fee for service reimbursement, patient values, medical success and financial success all can 
be misaligned. Many current attempts to link health outcomes to reimbursement are based on 
compliance with process measures with less emphasis on outcomes that matter most to patients, thus 
slowing transformation to higher-value team-based care.  Outcome measures that reflect the entire 
cycle of care are needed to assist both clinicians and administrators in improving quality and value of 
care. A comprehensive set of outcome measures for liver diseases is not currently available. 
Numerous researchers now are attempting to fill this gap by devising and testing outcome indicators 
and patients reported outcomes (PROMs) for the major liver conditions. These indicators will 
provide tools to implement a value-based approach for patients with chronic liver diseases to 
compare results and value of care between referral centers, to perform health technology assessment 
and to guide decision-making processes for health authorities.  This review sets the groundwork for 
implementing a value-based, patient-centered approach to chronic liver diseases within a health 
system. 
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The practice of Hepatology, once dominated by supportive treatment, has evolved into a 
highly complex discipline able to offer prevention and effective care for most acute and chronic liver 
diseases. In several geographic regions, including some western countries, the prevalence of liver 
disease is still significantly high. Despite availability of novel and effective treatments, the burden of 
liver diseases remains elevated, as access to new treatments is limited and not universally 
sustainable. Treatment of viral hepatitis, liver cancer, end-stage liver disease, alcoholic or metabolic 
or biliary liver diseases, requires costly medication and/or surgical procedures, including 
transplantation. Treatment of rarer chronic liver conditions is labor intensive and often requires 
specialized multi-disciplinary centers and orphan drugs  
Unfortunately, as therapy for liver disease blossoms, health care systems worldwide are 
facing problems sustaining support, and a significant number of patients may not receive appropriate 
treatment. As a further complication, measures taken by most health care systems to improve 
sustainability focus on cost-containment, reduction of coverage and system capacity.  As pointed out 
in foundational work on Value-Based Health Care, health care operates within a “zero sum 
competition” where fixed sums of resources are divided among providers, hospitals, pharmaceutical 
companies and other components of a disjointed health care system (1,2). As Albert Einstein 
remarked ‘we cannot solve a problem with the same thinking we used to create it.” In the last decade, 
a number of innovative solutions have been proposed by applying approaches and technologies 
typical of other economic and social disciplines.  An important example is value-based health care 
delivery that calls for re-orienting health care delivery towards value for patients (defined as 
outcomes that matter to patients per cost sustained to deliver the care) (1,2). Value-based health care 
delivery is increasingly becoming the dominant logic and strategy of health decision making, at 
every level, local practice, hospital, state and national and examples can be found in hepatology and 
other medical practices (3-8).  
Population health seeks the triple aim of better outcomes for a population, better experience 
for the patient and lower per capita costs (9). VBHC measures outcomes for each patient and these 
outcomes cumulate to affect population health. Thus, Value-based health care delivery is consistent 
with policy aiming to improve the health of the population. VBHC delivery attempts to understand 
the cost of care for each patient, providing insight that can be used for care process improvement and 
waste reduction. Those outcomes costs can be aggregated to show the average (or per capita) costs 
across a population. In fact, clinical decision-making and improvement require data on the outcomes 
and costs of patients with similar conditions, in addition to population averages. So through 
systematic meaningful outcome measurement the value-based delivery links to population health.  
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Health care for a given condition can be assessed using several measures of structure, process and 
outcome. The reader is referred to review articles detailing the differences among these measures 
(34). In brief, structure measures relate to the attributes of the setting in which care occurs and if 
these are conductive to safe and good care, while process measures inform about what is actually 
done to provide care based on best evidence or practice available. Finally, outcome measures capture 
the effects of care processes on the actual health and well-being of patients and populations (34) 
(respectively clinical outcomes and patient-relevant outcomes). 
 
 “Reimbursement and regulatory incentives for participating in VBHC. 
 The concept that provider payment should be linked to patient outcomes can be traced to 
Ernest Codman (1869-1940), a surgeon who first advocated “End Result” reimbursement. His ideas 
resulted in his loss of hospital privileges (Massachusetts General Hospital) and his being 
characterized by his colleagues as being “maniacally obsessed” with the idea that every hospital 
should follow every patient long enough to determine whether their treatment was successful (10). 
Modern advocates of value-based health care include Porter and Teisberg who have illustrated how 
current healthcare delivery systems fail to focus on competition at a disease or condition level and 
therefore raise barriers to high-value coordinated care, especially of complex conditions such as 
chronic liver diseases (1,2).  Despite enormous efforts to shift from volume-based strategy and 
fragmented care delivery service to value-based strategy with integrated care delivery teams, 
progress has been slow because measures of health outcomes that reflect what matters to patients 
and that track these outcomes throughout the full cycle of care are scarce (11).  As an example, the 
National Quality Measures Clearinghouse contains nearly 2000 quality indicators, but 7% are actual 
outcomes and less than 2% are patient-reported outcomes (12).  The Hospital Compare website 
maintained by Centers for Medicare and Medicaid Services (CMS) includes 123 different 
measures, of which 102 track process compliance (13).  
 In the United States, infrastructures designed to link patient and population health outcomes 
to provider reimbursement has been defined in several publications and legislative acts.  In March 
2011, the Agency for Health Care Research and Quality  published the National Quality Strategy for 
Quality Improvement in Health Care , in response to a mandate contained within the Patient 
Protection and Affordable Care Act (ACA). The overarching recommendations from this report 
include a) a commitment to a defined national strategy for achieving highest value, b) a process to 
implement and refine that strategy, c) proposals for care delivery through systems that emphasize 
clinical coordination, and d) a movement to value-based reimbursement based on metrics that 
reflect health outcomes, quality of care, access to care, population-based disparities, and efficiency 
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(14). Additionally, ACA mandated that the CMS become a proactive driving force in moving away 
from fee for service payment to providers.  As such, CMS changed from a passive payer to the key 
driver towards value-based health care, as Porter and Teisberg discussed (2). After the November 
2016 election results, the ACA may be repealed or significantly altered, but legislation mandating 
the migration to value-based care (Medicare Access and CHIP Reauthorization Act or MACRA) 
was passed with bi-partisan support and may remain in force (see below). 
 The National Quality Strategy, published in 2011, helped corral multiple disparate quality 
improvement initiatives into a more coordinated effort with six domains (priorities) as organizing 
principles (14). Interestingly, none of the principles focused on patients’ functional outcomes or 
relief from pain and suffering that occurs during or due to their health care (8). The National 
Quality Forum , National Priorities Partnership and the Measures Application Partnership (see ref 7 
for further discussion) worked to develop quality indicators and outcome measures.  Unfortunately, 
as Porter et al have pointed out, the measures were created by specialty societies working 
independently and emphasizing process metrics strictly within control of their constituent providers 
at single points of care (2,17). Generally, process measures are easier to achieve agreement upon 
since they are controllable by care providers (2). Clinical teams surely need to understand their 
processes and ensure that these processes are safe and appropriate; however, process measures track 
inputs rather than results for patients. Process measures may not be indicative of patients’ outcomes, 
nor do they follow results throughout the entire cycle of care for complex patients such as those 
with chronic liver diseases.  
 MACRA, signed into law in 2015, accelerated the shift towards value-based reimbursement. 
On May 9, 2016, CMS published a “Proposed Rule” open for public comment detailing the 
structure of Medicare value-based reimbursement and metrics that will be used.  As a result of 
public commentary and feedback, CMS modified the ultimate structure of MACRA as published in 
the “Final Rule” in October 2016.  Essentially, providers that care for a threshold number of 
Medicare beneficiaries are mandated to participate in one of two options that link payment to 
clinical results or face substantial payment reductions for Part B Medicare payments. 
(https://www.federalregister.gov/documents/2016/11/04/2016-25240/medicare-program-merit-
based-incentive-payment-system-mips-and-alternative-payment-model-apm) 
The first option is termed Merit-based Incentive Payment System. This option rests on 
existing incentive programs and combines three aspects of a provider’s care into a single value that 
is used to modify Part B Medicare payments.  The four components are a) the clinician’s 
participation in Medicare’s Physician Quality Reporting System , b) adoption of electronic medical 
records as defined by Meaningful Use (MU) and c) a practice improvement program and d) an 
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assessment of cost derived from Medicare claims called a Quality and Resource Use Report 
(QRUR).  Medicare initially estimated that 12,608 gastroenterologists (including hepatologists) will 
have allowed Part B charges totaling $1.6 billion and the MIPS program will have an aggregate 
positive payment adjustment of $34 million compared to historical trends.  Thirty-eight percent of 
gastroenterologists were estimated to have a negative payment adjustment. (data on file at 
www.gastro.org). With publication of the Final Rule, requirements eased somewhat so the burden 
on providers was lessened.  
 The second option practices may choose for Medicare reimbursement is termed an 
“Alternative Payment Model” (APM).  While still being fully defined, practices can choose to 
assume financial risk for outcomes by using bundled payments, belonging to an accountable care 
organization or incorporating other emerging financial and clinical risk models. As defined in the 
Final Rule, neither MIPS nor APM’s truly capture digestive disease-related health outcomes that are 
important to patients, payers and purchasers of care. External payment incentive programs are 
difficult to define and administer and are subject to constraints mandated by medical specialty 
societies that are responsible for creating metrics.  The Department of Health and Human Services 
has set goals of having 90% of Medicare’s traditional fee-for-service payments linked to quality by 
2018 and of shifting 50% of all reimbursement into APM’s by the same date (18). Despite these 
goals, current programs still fall short of the ultimate goal of supporting value-based care with valid 
outcome measures that are meaningful and clear to patients as well as providers, and that separate 
excellent from merely competent care.  
 Shifting from volume to value-based care using the current infrastructure and process 
measures will continue to be fraught with difficulties and will engender cynicism and frustration 
among providers. Physician burnout, resulting from multiple new regulations included in the 
MACRA legislation, conversion to a new diagnostic coding system and adoption of electronic 
medical records , is real and jeopardizes the quality of patient care.  If, however, hepatologists can 
shift the focus away from rewards for volume and towards rewards for providing high value care 
that fosters competition to improve outcomes for patients across the full cycle of their care, we 
believe a sense of professionalism and satisfaction can be restored.  
 
 
Clinical Outcome indicators for Value-Based Care in Hepatology 
 Measures specific to hepatology have been virtually non-existent within the current incentive 
payment structure (19), so developing a new set of measures is important to advance value-based 
care and accelerate improvement in the measured outcomes.   Hepatitis C-specific measures have 
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been part of Physician Quality Reporting Systems since 2008 but are all process measures.  These are 
currently under review and none reflect long-term patient outcomes or outcomes during care.  Others 
have developed preliminary recommendations focused on managing a population with chronic liver 
disease over a year’s episode and utilizing the strength of health system-wide electronic records (20).   
Work to develop valid assessment of outcomes for patients with cirrhosis has been advanced by 
rigorous definition and the creation of new measures are in development (see below). 
Value-Based Medicine is entering the field of Hepatology. Studies applying these concepts to 
liver diseases have begun to appear in high impact specialty journals (21-25), and ad hoc symposia 
have been organized by major international (AASLD and EASL) and national (AISF) liver societies. 
The concept of VBHC is different from that of evidence-based medicine (EBM), as it is based on 
outcome data, rather than guidelines. EBM and VBHC, though are not mutually exclusive, as the 
first is used to define procedures, while the second tests the clinical and economic outcomes of those 
procedures. EBM, and the concept of appropriateness, had an important impact in reducing the risks 
and the costs associated with the management of patients with liver diseases. A range of process 
indicators for liver disease is also available. Among others, the study from Kanwal et al(22,23) 
deserves a special mention for its effort to provide evidence-based process indicators for the 
treatment of patients with liver cirrhosis. While useful to guide treatment, process indicators do not 
provide information about clinical outcome and have a short life-span due to learning and innovation, 
and may have a weak correlation with the actual outcomes. On the other hand, the systematic 
measurement of clinical outcomes over an adequate period of observation provides the information 
needed to drive practice improvement and cost reduction at the patient level, and ultimately increase 
the sustainability of care (1-3,15).  
To be applicable for VBHC, outcomes measures need to capture the full cycle of care, not just 
a single encounter and not only at a distant time. For example, measuring only the inpatient mortality 
in cirrhotic patients with spontaneous bacterial peritonitis  would miss the three-month mortality due 
to kidney failure that is preventable using albumin infusion during the acute episode. At the other 
extreme, waiting until end of life to assess avoided disease progression would delay the learning 
about improved functional outcomes and reduced pain during the patients’ lives. Furthermore, 
indicators should be easy to collect and be generated from data obtained from the daily practice and 
from patients (1-4,11-13, 16).  
Because of the long natural history of liver diseases, in addition to long-term outcomes, such 
as transplantation or death, surrogate end-points are needed. Unfortunately, these are available and 
validated only for a few conditions. The problem can be approached by tracking patient-reported 
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functional outcomes throughout the cycle measuring not only if, but how well the patient 
lives(15,16).  
Progression to intermediate stages also represents outcomes during the cycle. In most chronic 
liver conditions, no matter the etiology, the patient progresses through a series of defined stages from 
chronic hepatitis to compensated cirrhosis, to decompensated cirrhosis or/and hepatocellular 
carcinoma and eventually transplant or death. The risk of progressing from one stage to the other 
varies according to the specific etiology, treatment, and comorbidities. Each of these stages 
represents a measurable outcome to avoid and is characterized by a specific functional status.  
 For example, in Type 2 diabetes, long natural history elapses before kidney failure, blindness 
or gangrenous foot ulcers develop. Rather than wait for these major events, relevant outcomes during 
care can be tracked over time, measuring the changes in patients’ functional capabilities over time 
during care.  These measures shed light for patients and their care teams on improvement or 
reduction in health outcomes over time and throughout the care cycle without waiting for years to 
make meaningful assessments (8). Patient reports of these measures can be collected as part of 
ongoing clinical practice. These ongoing assessments are particularly important because Type 2 
diabetes is a reversible disease, so outcomes during care indicate whether the patient is succeeding 
with management or progressing to more advanced stages disease. 
Similarly, in most liver diseases, (from viral hepatitis, to alcoholic and metabolic and 
autoimmune liver diseases), effective treatment is possible and leads to significant reduction in the 
risk to progress to cirrhosis and its complications. Also in patients that have already progressed to 
cirrhosis, etiologic treatment, life-style changes and treatment of comorbidities can significantly 
reduce the risk of decompensation, whereas, management of complications, early referral for 
transplantation and critical care management, will improve survival.  
A comprehensive set of outcome measures compatible with VBHC requirements is not yet 
available, but work is in progress and several studies have been reported at international meetings 
(26-30). Liver units interested in adopting a VBHC approach need outcome measurements to 
document their own improvement over time, for comparing outcomes and value of care between 
referral centers, as well as for fact-based decision-making. Each institution should collect measures 
that can better capture each specific organizational reality. Even though the numerical value of each 
measure clearly varies according to local practices and organizations, its measurement is key to 
performing local, national and international benchmarking. Plus, every organization can benchmark 
against its own previous measures to track improvement. Moreover, as these measures are used, they 
evolve as clinical teams suggest refinements to the measures as well as ways to improve patients’ 
outcomes (11-17).  
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A comprehensive set of outcome measures for hepatologists could be used for a range of 
purposes, from implementation of quality improvements to measuring results among tertiary centers, 
sharing learning among centers, making referrals or seeking telemedical consults and reimbursing 
based on value of care. Last, but not least, outcome measures are a strong instrument to evaluate the 
value of novel drugs and technologies.  
Patient-level Value-Based Health Care Delivery 
 In VBHC, clinical outcome indicators are usually one component of a multidimensional 
outcome measure set, paired with a parsimonious choice of patient-reported outcome (PROs) for 
each major condition or stage. For example, The International Consortium of Outcome 
Measurement (www.ichom.org) has convened groups of clinicians and patients to choose validated 
measures for a number of conditions, not yet including liver disease.  
Establishing measure sets is a major undertaking. Only a few studies have focused on liver 
disease; however, the benefit to both the patients and the system, of developing or choosing 
validated PROs will be enormous. New studies will need to augment the existing quality of life 
metrics to capture the patient perspective on meaningful outcomes for specific conditions or 
specific sets of medical circumstances.  
The existential purpose of health care is to help patients improve their quality of life and 
dignity of death. The goal of increasing value for patients recognizes both the purpose of health care 
and the need to manage costs. At the level at which value is created, patients usually can readily 
identify the outcomes that matter (31).  For patients with a particular condition, a handful of 
functional outcomes describe significant differences in their quality of life – during the care 
experience and after completion. Patients with head and neck cancer are concerned not only with 
survival, but also with retaining the abilities to swallow, eat and talk. Patients with osteoarthritis 
want to be free of pain and able to pursue their normal activities. Measuring a small set of 
functional outcomes, not hundreds of processes, allows teams to accelerate improvement of those 
results. This supports professional excellence.  
Outcomes during care are critical measures for patients with chronic or lifelong conditions 
or patients at the end of life since the duration of care may be the rest of these patients’ lives. For 
every patient, the clinical team can track success with a small set of patient reported outcomes that 
reveal improvement or decline. From the patient perspective, three categories of outcomes are 
robust: capability (or functional outcomes), comfort (reduction in pain and anxiety due to the 
disease) and calm (reduction in the chaos of appointments, instructions and bills to regain time 
focusing on one’s life)(15).  In practice, comparison of these measures for individuals over time, 
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and analysis of trends across patients accelerates professional learning and improvement in value 
for patients(15,31). 
With appropriate risk adjustment, the multidimensional outcomes for patients as well as 
costs of care can be compared across different protocols, different clinicians, different clinical teams 
or different locations. By looking at results from many patients, physicians and teams can gain 
insight on whether their patients fare better or worse than similar patients that they have treated, 
than patients treated elsewhere or than patients treated with different care processes. This learning 
and the improvement it drives are the primary reasons for outcome measurement. Competition to 
improve results for patients with similar circumstances or conditions, rather than competition to 
have the most or best hospital facilities, drives ongoing improvement in value for patients and 
supports the inherent professional incentives of physicians and other clinicians.  
Because outcome measurement appeals to professionalism, it inspires improvement. The 
Martini Klinik, which has measured the functional outcomes of each of its prostate cancer patients 
for the past 10 years, has achieved remarkable improvement in its patients’ functional 
outcomes.(32). Its patients suffer from incontinence and impotence at roughly one-fifth of the 
national average for prostate cancer patients, despite Gleason scores indicating appropriate (and 
arguably even too-delayed) use of surgery (33). Its surgeons enjoy shared excellence and resulting 
professional satisfaction; though they are regularly recruited to be department chairs elsewhere, 
none have left the team. In contrast, trying to create quality-based pay before developing 
meaningful measures can create resistance to change. Rather than paying for process compliance 
(P4P), payment can support transition to value-based care delivery by enabling bundled payment for 
clinical teams that integrate patient care and measure outcomes. Bundled payment allows the teams 
to attract volume by achieving excellence, and benefiting from the efficiencies they gain through 
higher margins(2). Team-based pay also enables alignment of incentives within organizations paid 
by capitation, though most payer-provider systems still use fee for service or volume-based rewards 
for payment within their systems. The potential to align medical success with financial success 
makes value a sustainable goal for patients, clinicians and society, supporting the triple aim of 
population health.  
 
Conclusions 
The time has come for value-based health care principles in the field of hepatology to 
augment our current Evidence-based Medicine. Much remains to be done, in terms of developing 
patient-level outcomes and cost analysis. Investments are needed in terms of informatics 
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infrastructure and for funding outcomes research and the development of condition-specific Patient 
Reported Outcomes of capability, comfort and calm. The reward however will be huge, as this 
approach will re-orient competition and decision-making in health care from increasing volume of 
treatments to improving the value of the care for the patient. No matter how simple and obvious this 
statement may seem, its implications are enormous for the patients, for physicians and for society.  
Hepatologists also must work with health care systems to provide data on costs of care, the 
denominator of the value equation (4).  They must become leaders to generate and monitor both 
clinical and patient-reported outcomes that represent the numerator of value for patients and the 
professional aspirations of hepatologists. 
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Table 1  Frequently Used Acronyms  
 
AASLD  American Association for the Study of Liver Diseases 
ACA  Affordable Care Act 
AHRQ  Agency for Health Care Research and Quality 
CHIP  Children’s Health Insurance Program 
CMS  Centers for Medicare and Medicaid Services 
EASL  European Association for the Study of the Liver 
EBM  Evidence-Based Medicine  
MACRA  Medicare Access and CHIP Reauthorization Act 
MIPS  Merit-based Incentive Payment System 
MU  Meaningful Use 
 
P4P  Pay for Performance 
 
PRO  Patient-Reported Outcome 
PROMs                Patient Reported Outcome Measures  
QRUR  Quality and Resource Use Report 
SBP  Spontaneous Bacterial Peritonitis 
VBHC  Value-Based Health Care 
 
For the benefit of the reader the table lists a series of acronyms that are frequently used in 
publications and legislation concerning value-based health care. Not all of them are used in this 
manuscript 
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